- Home
- NOVT vs PTGX Comparison
NOVT vs PTGX Comparison
Compare NOVT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOVT
- PTGX
- Stock Information
- Founded
- NOVT 1968
- PTGX 2006
- Country
- NOVT United States
- PTGX United States
- Employees
- NOVT 3000
- PTGX N/A
- Industry
- NOVT Industrial Machinery/Components
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- NOVT Miscellaneous
- PTGX Health Care
- Exchange
- NOVT Nasdaq
- PTGX Nasdaq
- Market Cap
- NOVT 3.8B
- PTGX 4.0B
- IPO Year
- NOVT N/A
- PTGX 2016
- Fundamental
- Price
- NOVT $105.69
- PTGX $77.57
- Analyst Decision
- NOVT Hold
- PTGX Strong Buy
- Analyst Count
- NOVT 1
- PTGX 8
- Target Price
- NOVT $133.00
- PTGX $74.13
- AVG Volume (30 Days)
- NOVT 405.3K
- PTGX 1.6M
- Earning Date
- NOVT 11-04-2025
- PTGX 11-06-2025
- Dividend Yield
- NOVT N/A
- PTGX N/A
- EPS Growth
- NOVT N/A
- PTGX N/A
- EPS
- NOVT 1.69
- PTGX 0.80
- Revenue
- NOVT $956,880,000.00
- PTGX $209,180,000.00
- Revenue This Year
- NOVT $5.06
- PTGX N/A
- Revenue Next Year
- NOVT $6.89
- PTGX $243.08
- P/E Ratio
- NOVT $62.42
- PTGX $96.33
- Revenue Growth
- NOVT 6.34
- PTGX N/A
- 52 Week Low
- NOVT $98.76
- PTGX $33.31
- 52 Week High
- NOVT $184.11
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- NOVT 47.48
- PTGX 63.15
- Support Level
- NOVT $99.96
- PTGX $74.62
- Resistance Level
- NOVT $107.01
- PTGX $93.25
- Average True Range (ATR)
- NOVT 3.26
- PTGX 4.76
- MACD
- NOVT 0.88
- PTGX 0.80
- Stochastic Oscillator
- NOVT 72.23
- PTGX 49.44
About NOVT Novanta Inc.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.